Table 3.

Overall efficacy (BICR assessed) of entrectinib in patients with NTRK fusion-positive solid tumors, by tumor type.

		Baseline CNS metastasesa	ORR, n (%)	Median DoR, mo	Median PFS, mo	Median OS, mo
Tumor category	n	n (%)	(95% CI)	(95% CI)	(95% CI)	(95% CI)
Sarcoma	26	2 (7.7)	15 (57.7)	15.0	10.1	18.7
			(36.9–76.7)	(4.6–NE)	(6.3–13.7)	(14.5–NE)
Salivary (MASC)	24	1 (4.2)	20 (83.3)	NE	NE	NE
			(62.6–95.3)	(NE–NE)	(13.8–NE)	(NE–NE)
NSCLC	22	13 (59.1)	14 (63.6)	19.9	14.9	NE
			(40.7–82.8)	(10.4–29.4)	(6.5–30.4)	(20.8–NE)
Thyroid cancer	13	7 (53.8)	7 (53.8)	13.2	19.9	19.9
			(25.1–80.8)	(7.9–NE)	(6.5–33.8)	(14.5–NE)
Colorectal carcinoma	10	0 (0)	2 (20.0)	17.6	2.8	16.0
			(2.5–55.6)	(15.1–20.0)	(1.9–16.0)	(10.8–37.1)
Breast cancer	7	2 (28.6)	5 (71.4)	12.9	10.1	19.2
			(29.0–96.3)	(4.2–NE)	(5.1–NE)	(5.1–NE)
Neuroendocrine tumors	5	0 (0)	2 (40.0)	NE	15.6	40.5
			(5.3–85.3)	(11.1–NE)	(0.9–NE)	(28.6–40.5)
Pancreatic cancer	4	0 (0)	3 (75.0)	12.9	12.8	22.0
			(19.4–99.4)	(7.1–12.9)	(6.2–17.5)	(11.2–30.7)
Cancer of unknown primary	3	0 (0)	1 (33.3)	9.1	7.2	14.3
			(0.8–90.6)	(NE–NE)	(4.4–10.0)	(NE–NE)
Gynecologic	2	0 (0)	1 (50.0)	38.2	27.4	39.3
			(1.3–98.7)	(NE–NE)	(13.7–41.2)	(32.1–46.4)
Head and neck	2	0 (0)	2 (100.0)	NE	NE	NE
			(15.8–100.0)	(16.9–NE)	(17.6–NE)	(NE–NE)
Cholangiocarcinoma	1	0 (0)	1 (100.0)	9.3	12.0	23.4
			(2.5–100.0)	(NE–NE)	(NE–NE)	(NE–NE)
Adenocarcinoma of upper GI tract	1	0 (0)	1 (100.0)	29.0	30.0	NE
			(2.5–100.0)	(NE–NE)	(NE–NE)	(NE–NE)
Neuroblastoma	1	1 (100.0)	0 (0)	—	0.1	0.1
			(NA)		(NE–NE)	(NE–NE)

Note: Data cut-off August 31, 2020.

Abbreviations: GI, gastrointestinal; MASC, mammary analog secretory carcinoma; NA, not applicable; NSCLC, non–small cell lung cancer.

^aCNS metastases status determined by investigator.